OPKO Health, Inc. (OPK)

ModeX Therapeutics initiated a Phase 1/2a clinical trial for MDX2004 in October 2025. Labcorp completed its acquisition of select assets of BioReference Health's oncology and related clinical testing services businesses in September 2025. OPKO Health reported a net loss of $148.4 million in the second quarter of 2025, with consolidated total revenues of $156.8 million. The company's board authorized an additional $100 million for its common stock repurchase program. OPKO Health outlined a full-year 2025 revenue guidance of $675 million to $685 million and noted annualized cost savings of $19 million from workforce and footprint reductions within BioReference in the first quarter of 2025.

Demand seasonality for OPKO Health's products and services can be observed in certain areas. Reduced sales in the Chilean subsidiary due to a mild winter cold and flu season indicate seasonality for related products. The diagnostics segment, particularly BioReference Laboratories, may experience seasonal demand for services like infectious disease testing.

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company operating in the healthcare sector. Its core business is divided into Pharmaceuticals and Diagnostics. The pharmaceutical division offers products like Rayaldee, Somatrogon, and Varubi, and has been enhanced by the acquisition of ModeX Therapeutics, Inc. The diagnostics segment includes BioReference Laboratories, which provides a wide range of laboratory testing services, including the 4Kscore test.

OPKO Health, Inc. has a global presence with its headquarters in Miami, Florida, U.S. Key geographic operations include the U.S., Ireland, Chile, Spain, Israel, and Mexico. The company is expanding internationally, including a partnership with NextPlat to distribute products in China and Japan. OPKO has employees across five continents, and its Irish operation, EirGen Pharma, serves as a global supply chain hub.

There have been no specific events widely reported that have significantly impacted OPKO Health, Inc.'s brand reputation in the past year. In September 2018, the SEC filed a lawsuit against OPKO Health and its CEO, Phillip Frost, which was settled in December 2018, and the claims were resolved in January 2019. OPKO agreed to an injunction and paid a $100,000 penalty without admitting or denying the allegations.

Major owners of OPKO Health, Inc. include Frost Gamma Investments Trust (27.72%), Rubric Capital Management LP (6.03%), Holbrook (Bruce C) (5.09%), The Vanguard Group, Inc. (4.81%), Hsiao (Jane H) (4.18%), Frost Group, L.L.C. (3.80%), BlackRock Institutional Trust Company, N.A. (3.56%), GJN 2021 Trust (2.51%), EGN 2021 Trust (2.51%), and Geode Capital Management, L.L.C. (1.32%).